Publish date: 24 January 2023
Cancer researchers in Liverpool have been promised up to £1.5m to look into new treatments for the disease.
The money will go to the Experimental Cancer Medicine Centre – a collaboration between The Clatterbridge Cancer Centre and the University of Liverpool.
The funding has been made possible by a partnership between Cancer Research UK and the National Institute for Health and Care Research and will allow new treatments – including immunotherapies – for a wide variety of cancers to be developed, as well as improving existing treatments.
ECMCs work in conjunction with local NHS facilities to provide access to cutting-edge cancer treatments. Testing these treatments helps to establish new ways of detecting and monitoring the disease and to evaluate how it responds to the treatment.
Liverpool ECMC lead, Prof Dan Palmer, a consultant at The Clatterbridge Cancer Centre, said: “We are delighted Liverpool has secured this funding. Clinical trials are crucial to new and improved treatments becoming adopted as standard treatments by the NHS and this funding will allow us to further advance how we can treat cancer effectively.
“Thousands of patients have been provided with access to life-saving drugs and therapies through the Liverpool ECMC and this funding will benefit people with cancer in Merseyside and beyond.”
Clatterbridge has been part of Liverpool ECMC since the status was first awarded to the city in 2017 and this new funding will allow the collaboration to continue until at least 2027.
For more on this see: https://www.clatterbridgecc.nhs.uk/news/major-new-funding-clatterbridge-researchers